These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12043424)

  • 41. Focus on the funding and production of evidence rather than its publication.
    Sheldon T
    PLoS Med; 2005 Jul; 2(7):e222. PubMed ID: 16033316
    [No Abstract]   [Full Text] [Related]  

  • 42. Big pharma and American psychiatry.
    Sharfstein SS
    J Nerv Ment Dis; 2008 Apr; 196(4):265-6. PubMed ID: 18414119
    [No Abstract]   [Full Text] [Related]  

  • 43. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The intangible magic of celebrity marketing.
    Moynihan R
    PLoS Med; 2004 Nov; 1(2):e42. PubMed ID: 15578110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ethics in pharmaceutical advertising.
    Lober CW
    Dermatol Clin; 1993 Apr; 11(2):285-8. PubMed ID: 8477540
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Left ventricular hypertrophy. Recent aspects of diagnosis and therapy].
    Schmieder RE; Schneider MP
    MMW Fortschr Med; 2002 Oct; 144(42):45-6. PubMed ID: 12533997
    [No Abstract]   [Full Text] [Related]  

  • 47. [Tax payers have payed billions for the "blood pressure maffia's" actions].
    Järhult B; Lindahl SO
    Lakartidningen; 2003 May; 100(21):1917-8. PubMed ID: 12815880
    [No Abstract]   [Full Text] [Related]  

  • 48. Industry-to-physician marketing and the cost of prescription drugs.
    Chiong W
    Am J Bioeth; 2003; 3(3):W28-W29. PubMed ID: 14594480
    [No Abstract]   [Full Text] [Related]  

  • 49. Supreme Court decision may have major impact on drug industry.
    Spurgeon D
    CMAJ; 1993 Feb; 148(4):629-31. PubMed ID: 8431828
    [No Abstract]   [Full Text] [Related]  

  • 50. Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
    Bourassa MG
    J Am Coll Cardiol; 2005 Mar; 45(5):720-1. PubMed ID: 15734616
    [No Abstract]   [Full Text] [Related]  

  • 51. PLoS Medicine and the pharmaceutical industry.
    PLoS Medicine Editors
    PLoS Med; 2006 Jul; 3(7):e329. PubMed ID: 17149970
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Wiedermann CJ
    Lancet; 2002 Jun; 359(9324):2199; author reply 2203-4. PubMed ID: 12091002
    [No Abstract]   [Full Text] [Related]  

  • 53. Student rally. Med school attendees write ethics code on drug firms.
    Romano M
    Mod Healthc; 2002 May; 32(19):24, 26. PubMed ID: 12038157
    [No Abstract]   [Full Text] [Related]  

  • 54. [Has self-interest taken over ethics and morals within medicine?].
    Werkö L
    Lakartidningen; 2002 Aug; 99(35):3432-3. PubMed ID: 12362769
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Generic ARBs are coming.
    Harv Heart Lett; 2010 Jul; 20(11):6. PubMed ID: 20815090
    [No Abstract]   [Full Text] [Related]  

  • 57. [Promoting research and graduate education by the pharmaceutical industry--scientific progress or marketing strategy?].
    Eckardt VF
    Z Gastroenterol; 1999 Jul; Suppl 2():19-27. PubMed ID: 10472695
    [No Abstract]   [Full Text] [Related]  

  • 58. Drug marketing practices criticized.
    Wagner L
    Mod Healthc; 1990 Dec; 20(50):12. PubMed ID: 10108088
    [No Abstract]   [Full Text] [Related]  

  • 59. Restrictions on the conduct of advertising of medicinal products in Poland and their violations.
    Czerw A; Marek EM
    Acta Pol Pharm; 2013; 70(4):769-76. PubMed ID: 23923402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Who is to be trusted? On press reporters' assignments and agendas].
    Nyrén O
    Lakartidningen; 2002 Dec; 99(50):5110-2. PubMed ID: 12572305
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.